Release Date: December 22, 2016
Expiration Date: December 31, 2018 (subject to change)
- CE for this activity will not be available after this date.
Reference Number: 16092334-A
A post impact survey invitation will be sent to all learners who complete this activity (see below). Participation is completely optional.
Overview: Type 2 Diabetes Mellitus (T2DM) patients on metformin or basal insulin struggle with post-prandial glucose control and overall optimal HgA1c levels. Rapid acting insulin is often met with patient resistance for its lack of convenience, precise timing and potential adverse effects with hypoglycemia. The updated EASD/ADA position statement recommends an alternative therapeutic option with the medication class GLP-1RAs. This activity is designed to allow providers to overcome clinical inertia leading to stagnated subpar therapies and gain confidence and competency in implementing GLP-1RAs in T2DM patients with stagnated subpar therapies.
After completing this activity, the learner will be better able to:
- Discuss current patient-centered guidelines for achieving HbA1c targets in T2DM
- Discuss the pathophysiologic defects contributing to postprandial hyperglycemia in patients with T2DM
- Identify strategies for providing timely, individualized, evidence-based treatment options to improve post-prandial glucose control
- Increase competency in comparing pharmacokinetics and pharmacodynamics of prandial insulins vs. GLP-1RAs in patients on basal insulin who have not yet achieved HbA1c targets
- Evaluate clinical evidence regarding the safety, efficacy, and individualized use of GLP-1 RAs in combination with basal insulin
Angela Thompson FNP-C, CDE, BC-ADM
Celia Levesque RN, MSN, CNS-BC, NP-C, CDE, BC-ADM
This activity was planned in accordance with AANP Accreditation Standards and Policies and is supported by an unrestricted educational grant from Sanofi. Angela Thompson and Celia Levesque have no relevant relationships to disclose.
This educational activity may contain opinions of the speaker from their personal experience. The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
To complete the CE for this activity, review all the content, successfully complete on the online post-test and submit the online program evaluation.
Post Impact Survey:
Between 30 to 90 days after this activity is completed, AANP will send out an invitation to participate in a Post Impact Outcomes Survey (PI Survey) . Participation in the survey is optional and does not affect the credit earned. The PI Surveys help measure the overall impact of the education content, see how the material impacts practice behaviors and what changes are being made. This anonymous information is crucial in helping the Education department improve current activities as well as guiding AANP in planning future CE activities.
For questions about this online CE activity, or more information concerning the AANP CE Center, please contact the AANP CE Center Manager at CECenter@aanp.org.